Lietman PS, Schaad UB, McCracken GH Jr, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr. 1980;96(1):119–26.

Article  Google Scholar 

Salem F, Johnson TN, Hodgkinson AB, Ogungbenro K, Rostami-Hodjegan A. Does, “birth” as an event impact maturation trajectory of renal clearance via glomerular filtration? Reexamining data in preterm and full-term neonates by avoiding the creatinine bias. J Clin Pharmacol. 2021;61(2):159–71.

Article  CAS  PubMed  Google Scholar 

Dua’A A, Xu S, Luig M, Kim HY, Alffenaar J-W. Dosing of vancomycin and target attainment in neonates: a systematic review. Int J Antimicrob Agents. 2022;59:106515.

Article  Google Scholar 

Wong S, Davis A, Selby PR, Khoo R, Gwilt I, Stocker SL, et al. Application of user-centered co-design principles to address barriers in therapeutic drug monitoring. Ther Drug Monit. 2023;45(3):368–75.

Alrahahleh D, Xu S, Zhu Z, Toufaili H, Luig M, Kim HY, et al. An audit to evaluate vancomycin therapeutic drug monitoring in a neonatal intensive care unit. Ther Drug Monit. 2022;44(5):651–8.

Nieuwlaat R, Connolly SJ, Mackay JA, Weise-Kelly L, Navarro T, Wilczynski NL, et al. Computerized clinical decision support systems for therapeutic drug monitoring and dosing: a decision-maker-researcher partnership systematic review. Implement Sci. 2011;6(1):1–14.

Article  Google Scholar 

Han J, Sauberan J, Tran MT, Adler-Shohet FC, Michalik DE, Tien TH, et al. Implementation of vancomycin therapeutic monitoring guidelines: focus on Bayesian estimation tools in neonatal and pediatric patients. Ther Drug Monit. 2022;44(2):241–52.

Article  PubMed  Google Scholar 

Burton ME, Ash CL, Hill DP Jr, Handy T, Shepherd MD, Vasko MR. A controlled trial of the cost benefit of computerized Bayesian aminoglycoside administration. Clin Pharmacol Ther. 1991;49(6):685–94.

Article  CAS  PubMed  Google Scholar 

Jarugula P, Akcan-Arikan A, Munoz-Rivas F, Moffett BS, Ivaturi V, Rios D. Optimizing vancomycin dosing and monitoring in neonates and infants using population pharmacokinetic modeling. Antimicrob Agents Chemother. 2022;66(4):e0189921.

Article  PubMed  Google Scholar 

Aparicio PBM, Jimenez CMR, Saiz MDMG. Application of pharmacokinetic and pharmacodynamic principles (AUC/MIC) to individualize treatment with vancomycin in neonatal population. Basic Clin Pharmacol Toxicol. 2018;123(Supplement 4):33.

Google Scholar 

Chen J, Huang X, Bu S, Chen X, Zhou J, Liu X, et al. The relationship between vancomycin AUC/MIC and trough concentration, age, dose, renal function in Chinese critically ill pediatric patients. Pharmacol Res Perspect. 2021;9(6):e00885.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le J, Bradley JS. Optimizing antibiotic drug therapy in pediatrics: current state and future needs. J Clin Pharmacol. 2018;58(Suppl 10):S108–22.

CAS  PubMed  Google Scholar 

Huang H, Liu Q, Zhang X, Xie H, Liu M, Chaphekar N, et al. External evaluation of population pharmacokinetic models of busulfan in chinese adult hematopoietic stem cell transplantation recipients. Front Pharmacol. 2022;13: 835037.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thoma Y. Tucuxi: the software tool for the interpretation of blood drug concentrations. [cited 31/01/2023]. Available from: https://drive.switch.ch/index.php/s/7DquwHlvVi4ftql.

Dubovitskaya A, Buclin T, Schumacher M, Aberer K, Thoma Y. TUCUXI: an intelligent system for personalized medicine from individualization of treatments to research databases and back. In: Proceedings of the 8th ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics; 2017. p. 223–32.

Cunio C, Uster D, Carland J, Buscher H, Liu Z, Brett J, et al. Towards precision dosing of vancomycin in critically ill patients: an evaluation of the predictive performance of pharmacometric models in ICU patients. Clin Microbiol Infect. 2021;27(5):783.e7-783.e14.

Article  CAS  Google Scholar 

Narayan SW, Thoma Y, Drennan PG, Yejin Kim H, Alffenaar J-W, Van Hal S, et al. Predictive performance of Bayesian vancomycin monitoring in the critically ill. Critical Care Med. 2021;49(10):e952–60.

Article  CAS  Google Scholar 

Nix DE, Davis LE, Matthias KR. The relationship of vancomycin 24-hour AUC and trough concentration. Am J Health Syst Pharm. 2022;79(7):534–9.

Article  PubMed  Google Scholar 

De Cock RFW, Allegaert K, Sherwin CMT, Nielsen EI, De Hoog M, Van Den Anker JN, et al. A Neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res. 2014;31(3):754–67.

Article  PubMed  Google Scholar 

Frymoyer A, Stockmann C, Hersh AL, Goswami S, Keizer RJ. Individualized empiric vancomycin dosing in neonates using a model-based approach. J Pediatric Infect Dis Soc. 2019;8(2):97–104.

Article  PubMed  Google Scholar 

Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed. 1999;81(3):F221–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mulubwa M, Griesel HA, Mugabo P, Dippenaar R, van Wyk L. Assessment of Vancomycin pharmacokinetics and dose regimen optimisation in preterm neonates. Drugs R D. 2020;20(2):105–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother. 2004;48(4):1159–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee SM, Yang S, Kang S, Chang MJ. Population pharmacokinetics and dose optimization of vancomycin in neonates. Sci Rep. 2021;11(1):1–8.

Google Scholar 

Lo YL, van Hasselt JG, Heng SC, Lim CT, Lee TC, Charles BG. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination. Antimicrob Agents Chemother. 2010;54(6):2626–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehrotra N, Tang L, Phelps SJ, Meibohm B. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations. Pharmacotherapy. 2012;32(5):408–19.

Article  CAS  PubMed  Google Scholar 

Dao K, Guidi M, André P, Giannoni E, Basterrechea S, Zhao W, et al. Optimisation of vancomycin exposure in neonates based on the best level of evidence. Pharmacol Res. 2020;154: 104278.

Article  CAS  PubMed  Google Scholar 

Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, et al. Population pharmacokinetics of vancomycin in Japanese pediatric patients. Ther Drug Monit. 1998;20(6):612–8.

Article  CAS  PubMed  Google Scholar 

Capparelli EV, Lane JR, Romanowski GL, McFeely EJ, Murray W, Sousa P, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol. 2001;41(9):927–34.

Article  CAS  PubMed  Google Scholar 

Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M, Jacqz-Aigrain E. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child. 2013;98(6):449–53.

Article  PubMed  Google Scholar 

Oudin C, Vialet R, Boulamery A, Martin C, Simon N. Vancomycin prescription in neonates and young infants: toward a simplified dosage. Arch Dis Child Fetal Neonatal Ed. 2011;96(5):F365–70.

Article  CAS  PubMed  Google Scholar 

Germovsek E, Osborne L, Gunaratnam F, Lounis SA, Busquets FB, Standing JF, et al. Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data. J Antimicrob Chemother. 2019;74(4):1003–11.

Article  CAS  PubMed  Google Scholar 

Asbury WH, Darsey EH, Rose WB, Murphy JE, Buffington DE, Capers CC. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. Ann Pharmacother. 1993;27(4):490–6.

Article  CAS  PubMed  Google Scholar 

Schaible DH, Rocci ML Jr, Alpert GA, Campos JM, Paul MH, Polin RA, et al. Vancomycin pharmacokinetics in infants: relationships to indices of maturation. Pediatr Infect Dis. 1986;5(3):304–8.

Article  CAS  PubMed  Google Scholar 

Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther. 1994;56(2):169–75.

Article  CAS  PubMed  Google Scholar 

Silva R, Reis E, Bispo MA, Almeida AM, Costa IM, Falcão F, et al. The kinetic profile of vancomycin in neonates. J Pharm Pharmacol. 1998;50(11):1255–60.

Article  CAS  PubMed  Google Scholar 

de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther. 2000;67(4):360–7.

Article  PubMed  Google Scholar 

Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol. 2005;60(3):265–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NH. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol. 2007;63(1):75–84.

Article  CAS  PubMed  Google Scholar 

Marques-Minana MR, Saadeddin A, Peris JE. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br J Clin Pharmacol. 2010;70(5):713–20.

Article  CAS  PubMed  PubMed Central  Google S